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Ethnopharmacological relevance: Cedrela odorata L. (Meliaceae) is a native plant of the Amazon region
and its inner stem bark is used in the treatment of diabetes in the form of maceration in Brazilian popular
medicine. Until now, there is no scientiﬁc study on this activity. The present study was aimed at
evaluating the anti-hyperglycemic activity, anti-diabetic, toxicity, antioxidant and potential mechanism
of action of hydroethanolic extract of the inner stem bark of Cedrela odorata.
Material and methods: The inner stem bark extract of Cedrela odorata was prepared by maceration in 70%
ethanol for 7 days to obtain hydroethanolic extract of Cedrela odorata (HeECo). The preliminary
phytochemical analysis was performed according to procedures described in the literature. Selected
secondary metabolites detected were quantiﬁed by high performance liquid chromatography (HPLC).
Acute toxicity of HeECo was investigated in male and female mice with oral administration of graded
doses of HeECo from 10 to 5000 mg/kg. Subchronic oral toxicity study was done by oral administration of
HeECo (500 mg/kg) and vehicle for 30 days to both sexes of Wistar rats. Clinical observations and
toxicological related parameters were determined. Blood was collected for biochemical and hematolo-
gical analyses, while histological examinations were performed on selected organs. Anti-hiperglycemic
and antidiabetic effects were evaluated in streptozotocin-induced diabetic rats. In acute evaluation, the
animals received pretreatment with 250 and 500 mg/kg of HeECo, before carbohydrate overload. For
subchronic effect, the antidiabetic activity of HeECo was evaluated using the same doses for 21 days. At
the end of the treatments, the levels of triacylglycerols, malondialdehyde, total antioxidant status,
superoxide dismutase and glutathione peroxidase activities were evaluated in the plasma.
Results: The extract showed low acute toxicity. HeECo exhibited inhibitory activity against α-glucosidase and
caused a lowering in the peak levels of blood glucose in animals that received glucose overload by 36.7% and
24.1% in the area under the glucose curve (AUC). When the overload was sucrose, HeECo reduced the blood
glucose level by 44.4% without affecting AUC. Treatment with HeECo of the blood glucose of the diabetic
animals for 21 days did not lead to improvement in weight gain and regularization of the blood glucose level,
but reduced the triacylglycerol and malondialdehyde levels by 36.6% and 48.1%, respectively. The activity of the
antioxidant enzymes, superoxide dismutase and glutathione peroxidase were signiﬁcantly increased when
compared to diabetic control rats. HPLC analysis showed the presence of polyphenols, such as gallic acid, ()-
gallocatechin and (þ)- catechin, the latter is present in higher quantity.
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Conclusions: Collectively, these data showed that HeECo could blunt the postprandial glycemic surge in rats;
possibly through inhibition of alpha-glucosidase and positive modulation of antioxidant enzymes. Our ﬁndings
conﬁrmed the anti-hiperglycemic activity of HeECo in STZ- diabetic rats. Cedrela odorata is effective in
diminishing glucose levels in vitro and in vivo and in ameliorating oxidative damage that occurs in diabetes and/
or due to hyperglycemia in rats. According to our results, the efﬁcacy of Cedrela odorata preparation could be
due to the presence of active principles with different mode of actions at the molecular level, including
α-glycosidases and glucose transporter inhibitors and antioxidant property.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Diabetes is a worldwide health problem, due to its high prevalence
and because clinical course of the disease can lead to several
impairments, such as vision loss, chronic renal disease, macro- and
microvascular complications, and eventually result in physical inca-
pacity and death (Kawahito et al., 2009). The American Diabetes
Association (ADA) estimates that in 2012, expenditure on the treat-
ment of the diabetes and its complications was approximately $245
billion in USA (ADA, 2013).
It is now well established that the main cause of long-term
diabetes damage is hyperglycemia, which is indeed a major char-
acteristic of this pathology (DeFronzo and Abdul-Ghani, 2011).
Inhibitors of α-glucosidase, which catalyzes the ﬁnal step in the dige-
stive process of carbohydrates, can retard the uptake of dietary carb-
ohydrates and suppress postprandial hyperglycemia and may ﬁnd use
in the treatment of diabetic patients. The present generation of drugs
used in the treatment of diabetes has certain limitations, and they
sometimes lose their effect on glycemic control. Consequently, there is
need for the development of new drugs.
Studies have shown that certain plants and phytochemicals have
properties that improve the diabetic state. These properties include
insulinotropic action on pancreatic beta cells (Karthikesan et al.,
2010); enhancement of insulin signaling in the liver (Baviloni et al.,
2010), adipose tissue (Kim et al., 2009), and muscle (Yoon et al., 2013);
and reduction in intestinal glucose absorption (Alzaid et al., 2013;
Goto et al., 2012; Manzano and Williamson, 2010). Plants containing
antioxidant substances have also been shown to have beneﬁcial
effects on diabetes (Naik et al., 2013), as well as reducing the oxidat-
ive stress caused by hyperglycemia (Ahmed et al., 2014). Several
α-glucosidase inhibitors from plants have been screened and have
been shown to be of clinical importance (Yasuda et al., 2014).
Cedrela odorata a medicinal tree native to Brazil belongs to the
Meliaceae family. In Brazil, the plant is non endemic, and is present
in phyto-geographic areas of the Amazon, Caatinga, Cerrado and
Atlantic Forest, particularly, in the North, Northeast, Midwest, South-
east and South of Brazil. It is popularly referred to as “cedro”, “cedro
branco” and “cedro vermelho” (Campos et al., 1991; Leite and Lleras,
1993; Balbiany et al., 2013; González-Coloma et al., 2012; Stefano
et al., 2014). It is widely planted in the Tropicals and extensively used
in different parts of the world for diverse purposes, including as a
medicinal plant.
The ethnomedicinal uses of its bark include treatment of wound,
skin rashes, as emetic, general inﬂammations, hemorrhage, hemor-
rhoids, leucorrheal, malaria, as anti-ulcer agent, and spasmolytic
among others (Okorie and Taylor, 1968; Campos et al., 1991;
Longuefosse and Nossin, 1996; MacKinnon et al., 1997; Omar et al.,
2003; DeFilipps et al., 2004; Monteiro et al., 2011; Bieski et al., 2012).
In addition, there is a report that the root and trunk bark is used to
reduce fever and pain; the trunk is harvested to prepare a decoction
for abortive and the seeds are believed to have vermifugal properties
(Orwa et al., 2009). The anti-fungal, antibacterial, antimalarial, antil-
eishmanial and antitrypanosomal properties have been documented
in some studies (MacKinnon et al., 1997; Omar et al., 2003; González-
Coloma et al., 2012; Rosas-Piñón et al., 2012). Essential oils of Cedrela
odorata have been subjects of various investigations, including the leaf
and bark oil from different countries (Asekun and Ekundayo, 1999;
Maia et al., 2000; Villanueva, et al., 2009).
In a recent ethnopharmacological survey by our Research Group
conducted in the Vale do Juruena region of the Amazon, the fresh or
dry inner stem bark of Cedrela odorata was cited by the locals in
form of maceration decoction in the treatment of diabetes, malaria,
gastrointestinal ailments, wound healing and alleviation of cancer
symptoms (Bieski, 2014). In the case of diabetes treatment, the
solution that results from the maceration of about 50 g in 150 mL of
the solution of its inner stem bark is taken 2–3 times per day for a
period of 30 or more. There is no report of toxicity by the local
population that uses the plant as medicine (Bieski, 2014). The use of
its stem bark oil in diabetes treatment has also been related by the
population of S. Tomé and Príncipe (Martins et al., 2003).
Up to the present, there is no report on the investigation into
the anti-hyperglycemic effects of Cedrela odorata to the best of our
knowledge. The objective of the present investigation was there-
fore aimed at verifying the anti-hyperglycemic activity of the hydr-
oethanolic extract of inner stem bark of Cedrela odorata, in vivo
antioxidant property, and including evaluation of its potential
acute and subchronic toxicities.
2. Materials and methods
2.1. Botanical material
Inner stem bark of the Cedrela odorata L. (Meliaceae) used in this
study was harvested from Juína, Mato Grosso, Brazil (S15137,1390
W056105,1000 elevation: 348m). The plant name has been checked
with www.theplantlist.org (08/25/2014). Plant collection was author-
ized by the Juína Municipality Department of Agriculture, Mining and
Environment (No. 209/2011/FARMACO/FCM/UFMT), the Department
of Environment of Mato Grosso (No. 669540/2011/SEMA-MT) and the
National Council for Scientiﬁc and Technological Development – CNPq
(010728/2013-9). Voucher specimens were identiﬁed by Southern
Amazon Herbarium – HERBAM, Mato Grosso State University (UNE-
MAT), Alta Floresta campus, and the same was deposited at the same
Herbarium (identiﬁcation number BI-1078). Since Cedrela odorata is
not included in the list of endangered Brazilian plants, its collection
for the purpose of scientiﬁc studies does not require prior authoriza-
tion by Brazilian Institute of Environment and Renewable Natural
resources (IBAMA/MMA).
2.2. Plant extract preparation
The inner stem bark was dried at 40 1C and then ground in an
electric mill to obtain 680 g powder. The powdered plant material
was extracted by maceration in 70% hydroethanolic solu-
tion (1:10 w/v) for 7 days in order to obtain the aqueous ethanolic
extract. After extraction, the solvent was partially evaporated under
reduced pressure (600 mmHg) at 40±1 °C in a rotary evaporator
(model 801, Fisatom, Brazil). The extract was then lyophilized
(Lyophilizer model LL 1500, Heto, Italy) to obtain HeECo. The extract
was kept protected from light and stored at 2–8 1C until use. The
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extract yield per gram of dried powdered leaves was 12.7%. HeECo
was dissolved in 2% DMSO at the time of use.
2.3. Phytochemical analysis
2.3.1. Preliminary phytochemical screening and ﬁngerprint HPLC
analysis
Preliminary phytochemical tests for secondary metabolites present
in HeECo were performed according to the methods described by
Matos (2009), which rely on chemical reactions of coloration, pre-
cipitation and foam formation. Fingerprint analysis was performed by
HPLC using a Shimadzu model LC-10 Avp series, equipped with a LC-
10AD pump, degasser DGU-14A, UV–VIS detector (SPD-10A), column
oven (CTO-10A), equipped with a Rheoyne manual injection (loop
20 mL) and integrating CLASS LC-10. The sample was analyzed using a
reverse-phase column (Phenomenex Luna C18 5 mM, 2504.6 mm2)
and pre-column (Phenomenex C18, 43.0 mm2). Chromatographic
separationwas performed by isocratic elution of methanol/water/acetic
acid (1:18:1), ﬂow 1mL/min at 40 1C and UV detection at 280 nm. The
standards used were gallic acid (Vetecs 444), ()-gallocatechin
(Sigmas G6657), an (þ)-catechin (Sigmas C1251). The compounds
present in HeECo were analyzed qualitatively and quantitatively where
possible, and expressed in micrograms per milligram of extract,
correlating the area of the analyte with the standards' calibration
curve, with built in concentrations of 125, 250 and 500 mg/mL.
2.4. Animals
Albino mice Mus musculus, Swiss-Webster strain (25–30 g) and
albino rats Rattus norvergicus, Wistar strains (180–200 g) were used
in the in vivo studies. Animals were provided by the Central Animal
House of the Federal University of Mato Grosso (UFMT). The animals
were kept in a room where the temperature was maintained at
2471 1C under a 12 h light–dark cycle. The animals received a
commercial diet and water ad libitum. The experimental procedures
were performed in accordance with the Brazilian College of Animal
Experimentation (COBEA) and were approved by the UFMT Ethics
Committee for Animal Use under number 23108043016/10-6.
2.5. Toxicity evaluation
2.5.1. Acute toxicity (Hippocratic test)
This test was performed with 3 male mice and female mice per
group, each receiving a single dose of HeECo (10, 50, 250, 625,
1250, 2500 or 5000 mg/kg) or vehicle (2% DMSO) by orogastric
gavage, after an overnight fast of 18 h. The animals were housed in
individual polypropylene cages and observed for the ﬁrst 15 h
after administration of the extract, and then once a day for
2 weeks. General behavioral observations were recorded in an
adapted version of the table of Malone (1977). On the 15th day, the
animals were sacriﬁced by cervical dislocation and examined for
macroscopic signs of toxicity in the liver, kidneys, heart, lungs,
stomach, intestines, and spleen.
2.5.2. Subchronic toxicity
The procedure was performed according to the method described
by Chan et al. (1982). Male and female Wistar rats were placed in
individual metabolic cages and randomly distributed into one of the
following groups (n¼7–8): female control (FC); females treated with
500 mg/kg of HeECo (FT500); male control (MC); and males treated
with 500 mg/kg of HeECo (MT500). Control groups received vehicle (2%
DMSO) only. Treatment was administered orally, once a day for 30
days. Body weight of the animals was measured daily and other
parameters (food and water intake, urinary volume and feces) were
determined every 3 days. Rats were also observed for the presence of
signs and symptoms of toxicity. On the 31st day, after fasting for 14 h,
the animals were sacriﬁced and the blood collected for determination
of complete blood count (CBC) and biochemical analysis (glucose, urea,
uric acid, creatinine, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), total cholesterol, HDL cholesterol, LDL cholesterol,
triglycerides, alkaline phosphatase, total protein, albumin and globu-
lin) using a commercial kit (Labtest Diagnostica SA, Brazil). The liver,
kidney, stomach, spleen, heart, lungs, and brain were removed and
their relative weight [(organ weight/body weight)100] determined
before being placed in 10% formalin for histological analysis.
2.6. Histopathological study
Vital organs such as liver, kidneys and lungs were preserved for
histopathological analysis. The organs were ﬁxed in 10% formalin,
dehydrated in ethanol and clariﬁed in xylene. After processing, the
tissues were embedded in parafﬁn and then sectioned to a thick-
ness of 5 μm using a Hyrax M60 (Carl Zeiss MicroImaging GmbH,
Germany). The sections were stained with hematoxylin and eosin.
The tissues were examined under a microscope with a
40objective, in a random order and blind to the original animal
or group. The renal injury was based on degeneration of Bowman
space and glomeruli, degeneration of proximal and distal tubules,
vascular congestion and interstitial edema. The criteria for liver
injury were vacuolization of hepatocytes and pyknotic hepatocyte
nuclei, number of Kupffer cells and enlargement of sinusoids.
Moreover, the histopathological change of lungs was based on
congestion, edema, inﬂammation and hemorrhage. The microscopic
features of the organs of male and female HeECo-fed rats were
compared with the control group of each gender.
2.7. Antidiabetic activity
2.7.1. In vitro assay of α-glucosidase inhibition activity
The activity of the α-glucosidase enzymewas determined according
to the method of Nishioka et al. (1998) with minor modiﬁcations.
HeECo (50–120 mg/mL) and the substrate (1 mM p-nitrophenyl-α-D-
glucopyranoside) were incubated with the α-glucosidase enzyme (1 U/
mL) for 30min at 37 1C. The reaction was stopped by addition
of carbonate buffer (0.25 mol/L sodium bicarbonate and 0.25mol/L
sodium carbonate pH 10.0) and the concentration of p-nitrophenolate
was determined spectrophotometrically (405 nm). Acarbose (1.25–
7.5 mg/mL) was used as positive control. The concentration of extract
required to inhibit α-glucosidase activity by 50% (IC50) was determined
by linear regression.
2.7.2. Induction of diabetes
For induction of diabetes, male Wistar rats were fasted for 15 h
before intravenous administration of 40 mg/kg streptozotocin in
citrate buffer (0.01 M pH 4.5). Normal rats received vehicle intra-
venously. Diabetic animals with postprandial glucose between 250
and 400 mg/L were used experimentally.
2.7.2.1. Acute anti-hyperglycemic activity. The experiments were
conducted in diabetic and nondiabetic animals, 7 days after the
induction of experimental diabetes, according to the method of
Oliveira et al. (2008). After an overnight fast (15 h), the animals
received vehicle (nondiabetic animals – N and diabetic control – DC)
or HeECo at doses of 250 and 500mg/kg (DT250 and DT500 respectively)
or standard drugs (100mg/kg phlorizin –DF or 3mg/kg acarbose –DA).
Thirty minutes after treatment, the animals received an overload of
sugars, consisting of glucose (2.5 g/kg), sucrose (4.0 g/kg), or starch
(3.0 g/kg). Glycemia was determined until 180min after the overload
using an Accu-Chek Active glucometers. The area under the curve
(AUC) was determined for comparison of the results.
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2.7.2.2. Subchronic antidiabetic activity. The experiments were
conducted in diabetic and nondiabetic animals, 5 days after
induction of experimental diabetes according to the method of
Oliveira et al. (2008) as previously described. Diabetic rats were
divided into 4 groups, as follows: diabetic controls treated with
vehicle (DC group), diabetic animals treated with 250 mg/kg HeECo
(DT250 group), diabetic animals treated with 500 mg/kg HeECo
(DT500 group), and diabetic animals treated with 500 mg/kg
metformin (DMet group). All the animals received vehicle (2%
DMSO), HeECo, or metformin daily by orogastric gavage, once a
day for 21 days. Body weight, urinary volume, food and water intake
were measured daily, while blood and urinary glucose and urea were
measured every 5 days. Blood glucose and urinary urea were
determined using a commercial kit (Diagnostic Labtest SA, Brazil),
and urinary glucose by the method of Summerson et al. (1947). At
the end of treatment, the animals were euthanized for collection of
the blood, liver, retroperitoneal adipose tissue, epididimal adipose
tissue, soleus muscle, and extensor longus digitorius muscle. The
tissues were weighed and the relative weight of each was
determined. Liver glycogen content was quantiﬁed according to the
method of Carroll et al. (1956) and lipids according to the method of
Folch et al. (1957). Plasma levels of triglycerides, total cholesterol, and
HDL were also determined using a commercial kit (Labtest
Diagnostica SA, Brazil). The levels of LDL and VLDL cholesterol were
determined by the Friedewald equation (Friedewald et al., 1972) and
expressed in mg/dL.
2.8. Lipid peroxidation evaluation
The evaluation of plasma lipid peroxidation was performed as
described by Esterbauer and Cheeseman (1990) and was adapted for
96 well microplates. Brieﬂy, plasma was deproteinized (10% trichlor-
oacetic acid 1:1 v/v) and 100 mL of the sample was mixed with 100 mL
of 1% thiobarbituric acid dissolved in 0.05 M sodium hydroxide. The
mixture was then incubated at 100 1C for 10min, cooled, and the
malondialdehyde (MDA) concentration determined at a wavelength of
532 nm. Results are expressed in mmol MDA/L plasma.
2.9. Total antioxidant status (TAS), superoxide dismutase (SOD)
activity and glutathione peroxidase (GPx) activity
TAS, SOD activity and GPx activity were determined using
Randoxs commercial kit (TASs NX2332, Ransods SD125 and
Ransels RS505).
2.10. Statistical analysis
The data were tested for normality (Kolmogorov–Smirnov) and
expressed as mean7standard error of the mean (SEM). Statisti-
cally signiﬁcant differences between the nondiabetic group (N)
and diabetic controls (DC) were evaluated by unpaired Student's t
or Mann–Whitney test. The untreated diabetic animals and treated
animals (DT250, DT500, and DMet) were compared by one-way
ANOVA followed by Tukey post-test. Values of po0.05 were
considered statistically signiﬁcant. The 50% inhibitory concentra-
tion (IC50) was calculated by linear regression. The dose-response
curve was obtained by plotting the percentage inhibition versus
concentration. All analyses were performed using GraphPad Prism
5.0 for Windows (San Diego, California, USA).
3. Results
3.1. Preliminary phytochemical analysis
Preliminary phytochemical analysis revealed the presence of
phenolic compounds in the extract of Cedrela odorata.
3.2. Fingerprint analysis
Analysis by HPLC conﬁrmed the presence of phenolic com-
pounds detected in the preliminary phytochemical analysis. The
chromatographic proﬁle (ﬁngerprint) obtained by HPLC of HeECo
is shown in Fig. 1. Gallic acid and ()-gallocatechin were detected
in quantities above the detection limits of the calibration curves
and (þ)-catechin at a concentration of 6.39 mg of CAT/g of HeECo
(0.67% of the extract).
3.3. Acute toxicity
No behavioral alterations were observed in the animals at
doses up to 250 mg/kg. Mild analgesia was noted at doses from
625 to 5000 mg/kg but this effect was reversed after 8 h of
administration of HeECo in both male and female mice. However,
at doses from 2500 to 5000 mg/kg, further effect on the autonomic
system was noted, evidenced as piloerection and paw licking,
which was reversed after 4 h of HeECo administration.
No macroscopic changes were observed in the intestines, sto-
mach, spleen, liver, kidney, lung, and heart, nor were any mortality
recorded due to HeECo administration at all doses tested.
Fig. 1. HPLC ﬁngerprint of hydroethanolic extract of Cedrela odorata.
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3.4. Subchronic toxicity
No fatality was recorded during the four weeks experimental
period, in both control and experimental groups. No toxicity signs
like diarrhea, lethargy, sleep, tremors, convulsions, salivation, or
coma were observed in any group. Skin, eyes and fur color,
respiratory, circulatory, autonomic and central nervous systems,
somatomotor activity and behavior pattern were found to be
normal in all the experimental groups.
There was no statistically signiﬁcant difference in the body
weight, water and food intake, urinary volume, or weight of feces
(Supplementary material, S1) of HeECo-treated and non-treated
animals.
There were sporadic increases in the relative weight of the
kidney (20%, po0.05) and lungs (5.5%, po0.05) in the FT500 group
when compared to FC group (Table 1). However, these increases
were not accompanied by corresponding histopathological altera-
tions in these two organs. There was the presence of inﬂammatory
cells in the lungs, in both the vehicle and HeECo treated groups of
animals (Supplementary material, S1).
Biochemical analysis of the plasma revealed reductions only in
the ALT activity by 33.3% and 23.6% (po0.05) in the male and
female HeECo treated rats, respectively when compared to the
respective controls (Table 2).
Hematological analysis did not detect any alteration in the
animals as a result of HeECo treatment (Supplementary S1).
3.5. Antidiabetic evaluation
3.5.1. Alpha-glucosidase assay
The IC50 of HeECo was found to be 84.7 mg/mL, a much lower
value than that of acarbose (IC50¼5,115.5 mg/mL), the standard
used in this experiment.
3.5.2. Acute antidiabetic evaluation
3.5.2.1. Anti-hyperglycemic effect after overload of glucose, sucrose,
and starch. The baseline fasting blood glucose levels were similar in
both diabetic and nondiabetic animals, but impairment in glucose
tolerance was observed in the DC group as expected (Fig. 2).
The peak blood glucose level was 16774 mg/dL in the normal
control group. The peak level in the DC group was 140% (po0.05)
higher than the normal control. The glycemic level of DC group
remained higher throughout the experimental period. HeECo
showed signiﬁcant (po0.05) dose dependent reduction of the
fasting serum glycemia in streptozotocin induced diabetic rats at
250 and 500 mg/kg. In normal control rats, the blood glycemic
level returned to basal value after 90 min postprandial. HeECo had
blood glucose lowering effect on serum glucose concentration only
at 500 mg/kg and was similar to the effect seen in the DF group.
The AUC (determined by glycemia time) was 124% higher in the
DC group compared to the N group, and was signiﬁcantly reduced by
treatment with 500 mg/kg of HeECo. This effect was similar to
that of the positive control group treated with phlorizin (Fig. 3).
(N group¼16,2537318, DC group¼36,43372,268, DT250 group¼
32,35271,467, DT500 group¼27,66671,423, DF group¼25,0337
1,241 mg/dL120 min, po0.05).
Signiﬁcantly (po0.05) higher fasting blood glucose was
observed in the diabetic control group compared to the nondia-
betic group. There was increase in serum glucose after sucrose
load (Fig. 4a), reaching its peak within 30 min in all the groups
(N group¼13873, DC group¼437739, DT250 group¼294738,
DT500 group¼243769, po0.05). HeECo at 500 mg/kg caused a
reduction of 44.4% in the maximum concentration of serum
glucose after sucrose over loading. A similar effect was observed
in the acarbose (positive control) treated group.
The increase in the glycemia after starch overload was much
lower than the increases observed after administration of sucrose
or glucose. Neither the treatment with HeECo nor with acarbose
altered the peak glycemia or the AUC (Fig. 4b).
3.5.3. Subchronic antidiabetic effect
As shown in Table 3, all somatic parameters in the DC group
were signiﬁcantly altered due to the induction of diabetes. These
include the reduced gain in body weight despite increased food
and water intakes and increased urinary output. HeECo as well as
metformin treatments failed to blunt the alterations to the somatic
parameters caused by streptozocin treatment. However, the food
intake and urinary output in the DT500 were higher when
compared to the DMet group.
Results in Table 4 show that glycemia, urinary glucose and urea
were all persistently at higher levels in the DC group compared to
the N group. Treatment with HeECo had no effect on the altered
blood and urinary parameters evaluated, with similar values
encountered in all the diabetes induced groups, DT250, DT500 and
DC, with the exception of the lowered urinary glucose in the
metformin group (day 5, 15 and 20th, po0.05).
As shown in Table 5, diabetes induction caused increase in the
fructosamine and reduced hepatic glycogen contents at 21 day
evaluation. These aberrations were not modiﬁed by HeECo treat-
ments (250 and 500 mg/kg). However, HeECo effectively reduces
the serum triglycerides and VLDL cholesterol by 40.7%, 36.5% and
37.5%, 33.3% (po0.05), respectively. The standard drug effectively
restores the depleted hepatic glycogen to normal level resulting in
an increase of 119.2% (po0.05).
The relative weights of tissues did not differ between groups
(Supplementary data).
3.6. Antioxidant parameters
As seen in Table 6, the DC group displayed increased MDA
content and reductions in both GPx and TAS activities when
compared to the normal group. Treatment with HeECo at 500 mg/
kg (po0.05) was able to effectively attenuate the increase in the
plasma MDA concentration. Likewise, HeECo (250 and 500 mg/
kg) improved the SOD and GPx activities, restoring it to the
normal value, without altering the total antioxidant status.
However, metformin did not alter the oxidant status of the
diabetic animals.
4. Discussion
The inner stem bark of Cedrela odorata was selected for
antidiabetic evaluation, due to the high number of citations
Table 1
Relative weight (%) of tissues after 30-day treatment with hydroethanolic extract of
Cedrela odorata (HeECo) in male control rats (MC), male rats treated with 500 mg/
kg HeECo (MT500), female control rats (FC), and female rats treated with 500 mg/kg
HeECo (FT500). Data are expressed as mean7SEM (n¼7–8). Student's t test was
performed between the MC and MT500 groups, and the FC and FT500 groups.
Relative weight (%) FC FT500 MC MT500
Liver 3.0170.07 3.0270.05 3.0470.04 2.9870.05
Heart 0.3770.01 0.3670.01 0.3870.01 0.3570.01
Lungs 0.5370.02 0.6470.04a 0.5270.02 0.5870.04
Right kidney 0.3670.01 0.3870.01a 0.4070.01 0.4170.01
Left kidney 0.3670.01 0.3570.02 0.4170.01 0.4170.01
Stomach 0.7170.03 0.7570.02 0.6670.05 0.5470.03
Spleen 0.2670.01 0.2470.01 0.2370.01 0.2370.01
Brain 0.7470.02 0.7670.01 0.5570.01 0.5470.01
a po0.05 vs. FC.
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attributed to this plant in an ethnopharmacological survey
carried out in the Vale do Juruena, Mato Grosso state, Brazil
(Bieski, 2014).
Although medicinal plants products are considered to be of
lower risk compared with synthetic drugs, they are not completely
free from the possibility of toxicity or other adverse effects (Jordan
et al., 2010). This was why the World Health Organization as well
as several national and International bodies have issued docu-
ments detailing good practices in the safety assessment of herbals
(Jordan et al., 2010; Ekor, 2014; Kunle et al., 2012; Robinson and
Zhang, 2011).
Acute toxicity is usually an initial study performed for the main
purposes of: classiﬁcation and labeling, providing initial informa-
tion on the mode of toxic action of a substance, to help arriving at
a dose of a new compound and to help in dose determination in
animal studies (Balogun et al., 2014). To this end, acute toxicity
was carried out in both sexes of mice. The result shows that HeECo
is non-lethal at up to 5000 mg/kg. However, there were mild
reversible reactions which may be suggestive of potential phar-
macological property of the plant.
In subchronic toxicity study, no treatment-related clinical
symptoms or deaths were recorded during the course of the
experiment. Comparison of organ weights between treated and
untreated groups of animals has conventionally been used to
evaluate the toxic effect of the test substance in toxicological
experiments (Michael et al., 2007). We observed slight increase in
the right kidney and the lungs of female rats treated with HeECo.
These observations are of no toxicological importance for the
following reasons: the higher kidney weight occurred only in the
right kidney and was very minimal, there were no corresponding
alterations in the relevant biochemical parameters, nor were there
any signiﬁcant histological lesions suggesting damage to these
organs (Balogun et al., 2014; Mu et al., 2011). Moreover, the lung
weight has been considered useful mainly in inhalation studies
(Michael et al., 2007).
In subchronic toxicity study, there was a sporadic decrease only
in the ALT. Likewise, this was not accompanied with any clinical
signs, nor were there any signiﬁcant histopathological ﬁndings.
We therefore conclude that it is not treatment related and of little
toxicological importance (Carakostas and Banerjee, 1990).
The in vitro α-glucosidase inhibition assay shows that HeECo
possesses potent inhibitory effect on these enzymes. The inhibition
of intestinal α-glucosidases would delay the digestion and absorp-
tion of carbohydrates and, consequently, suppress postprandial
hyperglycemia and may help explain the anti-hyperglymic effect
of HeECo after overload of sucrose (Deng et al., 2012).
Fig. 3. Anti-hyperglicemic effect of HeECo – Diabetic (DC) and nondiabetic (N) rats
that received glucose overload (2.5 g/kg) after pretreatment with vehicle (N, DC),
HeECo (DT250 an DT500: 250 and 500 mg/kg of HeECo, respectively) or phlorizin (DF
– 100 mg/kg). Data are expressed as mean7SEM from 6–10 animals per group.
Signiﬁcantly different at *po0.05 versus normal group, #po0.05 versus diabetic
control and &po0.05 versus diabetic treated250 group.
Table 2
Biochemical parameters in plasma after 30 days of treatment with hydroethanolic extract of Cedrela odorata (HeECo) in male control rats (MC), male rats treated with
500 mg/kg HeECo (MT500), female control rats (FC), and female rats treated with 500 mg/kg HeECo (FT500). Data are expressed as mean7SEM (n¼7–8). Student's t test was
performed between the MC and MT500 groups, and the FC and FT500 groups.
Parameter FC FT500 MC MT500
Glucose (mg/dL) 108.5775.62 100.2572.84 96.1471.92 94.7171.94
Triglycerides (mg/dL) 119.29710.83 116.67714.87 78.8673.13 80.29713.35
Total cholesterol (mg/dL) 115.2977.64 120.6375.68 88.1474.15 86.8675.59
HDL cholesterol (mg/dL) 26.6471.14 28.3071.02 23.8770.81 23.0371.58
LDL cholesterol (mg/dL) 64.7477.02 64.5574.33 48.3173.47 47.7174.32
Urea (mg/dL) 54.7172.32 55.0073.19 44.0072.97 39.4371.29
Creatinine (mg/dL) 0.4470.01 0.4870.01 0.4170.01 0.3870.01
AST (U/L) 154.33710.55 154.17713.98 126.5078.29 122.5074.19
ALT (IU/L) 51.2072.63 42.4371.17a 56.6771.09 38.0072.01b
Alkaline phosphatase (IU/L) 291.00714.36 307.38720.32 379.43721.45 334.00744.55
Gamma glutaryl transferase (IU/L) 2.0070.22 2.0070.27 2.7170.18 2.5770.30
Total protein (g/dL) 6.1070.09 6.2470.14 5.9470.08 5.8470.07
Albumin (g/dL) 4.3470.05 4.3870.07 4.1970.09 4.1170.07
Globulin (g/dL) 1.7470.09 1.8870.16 1.6770.03 1.7070.04
ALT – alanine aminotransferase and AST – aspartate aminotransferase.
a po0.05 vs. FC.
b po0.05 vs. MC.
Fig. 2. Anti-hyperglicemic effect of HeECo – Diabetic (DC) and nondiabetic (N) rats
that received glucose overload (2.5 g/kg) after previous administration of vehicle
(N, DC), HeECo (DT250 and DT500: 250 and 500 mg/kg of HeECo respectively) or
phlorizin (DF, 100 mg/kg). Data are expressed as mean7SEM for 6–10 animals per
group. Signiﬁcantly different at *po0.05 versus normal group, #po0.05 versus
diabetic control group, &po0.05 versus diabetic treated group (250 mg/kg).
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The fact that this effect was more pronounced when glucose was
administered suggests that the extract may also be inhibiting glucose
transporters in the intestine. The inhibitory effect in the diabetic
HeECo-treated group was similar to the effect observed in the diabetic
phlorizin treated group. Phlorizin has an inhibitory effect on Naþ
glucose transporter 1 (SGLT1), a glucose transporter in the intestine.
SGLT1 is located in the apical membrane of enterocytes and GLUT2
(glucose transporter type 2) is found on the basolateral side. Luminal
glucose is transported into enterocytes by SGLT1 and then to the
outside of the cell by GLUT2. SGLT1 is a constitutive protein, while the
presence of GLUT2 in the membrane is increased in response to
increased glucose concentration (Manzano and Williamson, 2010).
Table 3
Somatic parameters obtained during 21 days treatment with HeECo in nondiabetic rats (N), diabetic control rats (DC), diabetic rats treated with 250 and 500 mg/kg HeECo
(DT250 and DT500), and diabetic rats treated with 500 mg/kg metformin (DMet).
Parameter N DC DT250 DT500 DMet
Initial body weight (g) 19177 21378 21977 21575 21978
Final body weight (g) 30577 267711a 25879 26575 28575
Body weight gain (g) 119710 5377a 3978 5075 66710
Food intake (g/day) 2471 3272a 3273 35.172b 2772
Water intake (mL/day) 3673 105710a 110717 129710 84710
Urinary volume (mL/day) 671 6877a 69713 8778b 35710
Data are expressed as mean7SEM (n¼6–7). Student's t test was carried out between the normal and control groups, and one way ANOVA followed by Tukey post-test was
carried out among diabetic groups.
a po0.05 versus N.
b po0.05 versus DMet.
Table 4
Postprandial blood glucose, urinary glucose and urea during 21 days of treatment with HeECo in nondiabetic rats (N), diabetic control rats (DC), diabetic rats treated with 250
and 500 mg/kg HeECo (DT250 and DT500), and diabetic rats treated with 500 mg/kg metformin (DMet).
Parameter Days N DC DT250 DT500 DMet
Glycemia (mg/dL) 0 13475 414737a 419732 407727 410733
5 11974 409717a 397718 387720 347733
10 12174 395740a 385731 375719 356738
15 12876 364732a 386766 385717 309745
20 12873 386724a 379728 396726 294748
Urinary glucose (mg/24 h) 0 371 57537806a 60337707 62817740 64337756
5 271 59737701a 56627640c 59967419c 27927547b
10 371 62677675a 702471220 85087537c 30037990
15 371 683671175a 53937846 80177763c 281371171b
20 271 59007519a 58617961c 80177857c 22067926b
Urinary urea (mg/24 h) 0 280754 10787111a 1195773 12347154 1143780
5 195727 12877131a 1267784 1403775c 911798
10 429744 14057227a 15147220 15567155 9947170
15 427736 12797135a 14207150 18757334c 8607117
20 256732 12727208a 11867136 16907300c 8657117
Data are expressed as mean7SEM (n¼6–7). Student's t test was carried out between the normal and control groups, and one way ANOVA followed by Tukey post-test was
carried out among diabetic groups.
a po0.05 versus N.
b po0.05 versus DC.
c po0.05 versus DMet.
Fig. 4. Blood glucose levels after overload of (A) sucrose (4.0 g/kg) and (B) starch (3.0 g/kg) in rats after pretreated with vehicle, HeECo or acarbose. N: nondiabetic; DC:
diabetic control; DT250 and DT500: diabetic treated with 250 and 500 mg/kg of HeECo, respectively; DA: diabetic treated with 3 mg/kg of acarbose. Data are expressed as
mean7SEM from 5–6 animals per group. Signiﬁcantly different at *po0.05 versus normal group, #po0.05 versus diabetic control.
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This hypothesis needs further studies for conﬁrmation. Therefore,
GLUT2 is a possible point therapeutic target for potential antidiabetic
agents (Kwon et al., 2007).
Inhibition of glucose absorption can be important in the treat-
ment of diabetic patients in order to prevent postprandial hypergly-
cemia. Polyphenols, such as phenolic acids and tannins, inhibit the
absorption of glucose by GLUT2 and SGLT1 in the intestine (Manzano
and Williamson, 2010). The main components of HeECo are gallic
acid, ()-gallocatechin, and in higher quantity is the (þ)-catechin.
Gallate catechins present in green tea (Camelis sinensis) have been
shown to reduce glucose absorption by inhibition of SGLT1 (Manzano
and Williamson, 2010). Therefore, we can attribute, at least in part,
the reduction in hyperglycemia to the presence of catechins in
HeECo. Substances such as ﬂavonoids, anthocyanins and stilbenes
have also been shown to inhibit glucose uptake in the vesicles of
brush border membrane of the intestine and in Caco-2 human
epithelial colorectal cells (Alzaid et al., 2013; Goto et al., 2012).
The administration of subchronic doses of the extract did not
reduce blood glucose level, urinary glucose and urea that were
altered in the diabetic state. However, by the 21st day of treatment
there was a reduction in postprandial triglyceride levels. Supple-
mentation of a diet with a mix of several substances found in green
tea, such as epicatechin, ()-epigallocatechin, ()-epicatechin
gallate and ()-epigallocatechin gallate, has been shown to reduce
fatty acids synthesis by inhibiting fatty acid synthase (FAS) and
pancreatic lipase enzymes and consequently reducing triglyceride
absorption (Ikeda et al., 2005). Further, Puig et al. (2008) showed
that epigallocatechin-3-gallate inhibits FAS in both in vitro and
in vivo assays using human breast adenocarcinoma SK-BR-3 cells.
Nabi et al. (2013) showed that the roots of Piper longum
have antihyperglycemic and hypolipidemic following chronic
administration. This differs from our observations, in that treat-
ment with HeECo, caused reduction in triglycerides after sub-
chronic treatment and reduction of hyperglycemia only in the
acute assessment.
Some authors have reported reduction in lipid levels associated
with reduced oxidative stress in animal models. Shimoda et al.
(2009) showed that ddY mice, which have marked postprandial
hyperlipidemia, have reduced serum triglycerides after receiving a
diet rich in lipids for 13 days, and treatment with a polyphenols
rich extract of walnut (Juglans regia L.). This effect was attributed
to increased PPARα expression in the liver. Kim et al. (2013)
showed that in apoE / mice, that received for 4 weeks of a diet
rich in fat and cholesterol and supplemented with polyphenols of
Aronia melanocarpa (containing gallic acid and (þ)-catechin)
reduced serum cholesterol levels without affecting expression of
enzymes involved in the metabolism of cholesterol and lipids. This
treatment also increased catalase and plasma paraoxonase activity
in the said study.
Insufﬁcient antioxidant capacity coupled with excessive forma-
tion of reactive oxygen-free radicals may damage cellular compo-
nents. At the cellular level, increased cell death is believed to be
sustained by high-glucose in many cell types (Juárez-Reyes et al.,
2015; Yonguc et al., 2015).
Our results show that HeECo improved the antioxidant status
of the diabetic animals evidenced by the increased in the enzy-
matic activity of SOD and GPx and a reduction in the plasma lipid
peroxidation. A study by Rashed (2014) demonstrated the potent
in vitro antioxidant activity of stem bark extracts of Cedrela
odorata. Zargar et al. (2014) showed that the hydroethanolic and
aqueous extract of Paeonia emodi R. has in vitro antioxidant
activity, and increases the activity of SOD and GPx enzymes.
Table 6
Plasmatic content of malondialdehyde (MDA), total antioxidant status (TAS) and enzymatic activity of superoxide dismutase (SOD) and gluthathione peroxidase (GPx) after
21 days of treatment with HeECo in nondiabetic rats (N), diabetic control rats (DC), diabetic rats treated with 250 and 500 mg/kg HeECo (DT250 and DT500), and diabetic rats
treated with 500 mg/g metformin (DMet).
Parameter N DC DT250 DT500 DMet
MDA (mmol/L) 1.8870.31 5.6170.48a 3.3270.33 2.9170.52b 3.9271.00
TAS (mmol/L) 1.1770.03 0.9770.03a 1.0670.06 1.1370.02 1.1170.05
GPx (x103U/L) 16.1570.51 11.3770.72a 15.6370.52bc 14.7770.34bc 12.2370.52
SOD (U/L) 42.3070.26 40.8970.66 60.7271.75bc 60.7671.14bc 41.9670.36
Data expressed as mean7SEM (n¼6–7). Student's t test was carried out between the N and DC groups, and one way ANOVA followed by Turkey post-test was carried out
among diabetic groups.
a po0.05 versus N.
b po0.05 versus DC.
c po0.05 versus DMet.
Table 5
Biochemical parameters after 21 days of treatment with hydroethanolic extract of Cedrela odorata (HeECo) in nondiabetic rats (N), diabetic control rats (DC), diabetic rats
treated with 250 mg/kg and 500 mg/kg HeECo, (DT250 and DT500), and diabetic rats treated with 500 mg/g metformin (DMet).
Parameter N DC DT250 DT500 DMet
Fructosamine (mmol/L) 11277 198712a 168715 180721 144719
Serum triglycerides (mg/dL) 132715 123715 7376bc 7878bc 142710
Total cholesterol (mg/dL) 110710 10976 10077 11378 110710
HDL cholesterol (mg/dL) 4674 4276 4776 4178 5175
LDL cholesterol (mg/dL) 3775 4473 41713 46713 2878
VLDL cholesterol (mg/dL) 2673 2473 1571bc 1672bc 2872
Hepatic glycogen (mg/g tissue) 6273 2673a 2772c 2875c 5777b
Hepatic fat (mg/g tissue) 3171 3571 3572 3971 2574
Data expressed as mean7SEM (n¼6–7). Student's t test was carried out between the normal and diabetic control groups, and one way ANOVA followed by Tukey post-test
was carried out among diabetic groups.
a po0.05 versus N.
b po0.05 versus DC.
c po0.05 versus DMet.
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Furthermore, in Wistar rats fed a high-fat diet, 30 days of
treatment with this extract resulted in a reduction in triglycerides
and LDL cholesterol, suggesting an association between the anti-
oxidant activity reducing atherosclerotic risk. The antioxidant
property may thus be said to be responsible, at least in part, for
its ameliorating effect of the diabetic state. However, it did not the
total antioxidant status of the animals. Explanation for this
requires further studies.
The values of fructosamine showed no improvement at the end of
the study period, conﬁrming the lack of effect on blood glucose levels
in subchronic treatment. Gris et al. (2011) showed that the polyphe-
nols present in red wine (rich in stilbenes and tyrasol) can increase the
total antioxidant status of plasma, reduce the content of MDA and
protein carbonyls, increase liver SOD and catalase activity, reduce total
and LDL cholesterol, reduce triglycerides and increase HDL cholesterol
in C57BL6 LDL knockout mice after 30 days of treatment.
We conclude that the HeECo extract may be effective in
reducing postprandial hyperglycemia and damage from oxidative
stress resulting from high levels of glucose. These results taken
together justify the use in ethnomedicine of this plant in the
treatment of diabetes.
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